These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21240588)

  • 1. [Drug treatment of cystic fibrosis - cost patterns and savings potential for outpatient treatment].
    Baltin CT; Smaczny C; Wagner TO
    Med Klin (Munich); 2010 Dec; 105(12):887-900. PubMed ID: 21240588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.
    Heimeshoff M; Hollmeyer H; Schreyögg J; Tiemann O; Staab D
    Pharmacoeconomics; 2012 Sep; 30(9):763-77. PubMed ID: 22690685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results].
    Eidt D; Mittendorf T; Wagner TO; Reimann A; Graf von der Schulenburg JM
    Med Klin (Munich); 2009 Jul; 104(7):529-35. PubMed ID: 19618138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost reducing of or by drugs. More rationality and efficiency in drug therapy].
    Glaeske G
    Internist (Berl); 2010 Aug; 51(8):1057-60, 1062-3. PubMed ID: 20552155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost reduction with project based prescription of generic ACE inhibitors].
    Wolzt M; Ohrenberger G; Reichardt B
    Wien Klin Wochenschr; 2003 Jan; 115(1-2):23-8. PubMed ID: 12658907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost of pharmacologic treatment and their determinants in ambulatory care of cystic fibrosis patients].
    Stelmach I; Korzeniewska A; Stelmach W
    Pneumonol Alergol Pol; 2004; 72(9-10):415-9. PubMed ID: 16021997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic public health significance of generic drugs].
    Tschabitscher D; Waechter F; Müllner M
    Wien Klin Wochenschr; 2009; 121(11-12):365-71. PubMed ID: 19626293
    [No Abstract]   [Full Text] [Related]  

  • 8. The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective.
    Frey S; Stargardt T; Schneider U; Schreyögg J
    Pharmacoeconomics; 2019 Aug; 37(8):1029-1039. PubMed ID: 30949989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prescriptions for psychotropic drugs: results and comments on the 2005 prescription drug report].
    Fritze J
    Nervenarzt; 2006 Mar; 77(3):376-83. PubMed ID: 17078120
    [No Abstract]   [Full Text] [Related]  

  • 10. [[Prescriptions for psychotropic drugs: results and comments on the 2007 prescription drug report].
    Fritze J
    Nervenarzt; 2008 Nov; 79(11):1337-45. PubMed ID: 19002733
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study.
    Heinze G; Hronsky M; Reichardt B; Baumgärtel C; Müllner M; Bucsics A; Winkelmayer WC
    Appl Health Econ Health Policy; 2015 Apr; 13(2):193-205. PubMed ID: 25536928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016.
    Grosse SD; Do TQN; Vu M; Feng LB; Berry JG; Sawicki GS
    Pediatr Pulmonol; 2018 Dec; 53(12):1611-1618. PubMed ID: 30381911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis.
    Levy JF; Rosenberg MA; Farrell PM
    Pediatr Pulmonol; 2016 Dec; 51(12):1295-1303. PubMed ID: 27740724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Health care too costly? Saving more than 10 million euros in 2 months!].
    Rappert B
    MMW Fortschr Med; 2003 Nov; 145(47):65. PubMed ID: 14725043
    [No Abstract]   [Full Text] [Related]  

  • 15. [Regress risk in aut idem prescribing].
    Zimmermann GW
    MMW Fortschr Med; 2014 Aug; 156(14):13. PubMed ID: 25195382
    [No Abstract]   [Full Text] [Related]  

  • 16. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
    Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S
    Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Health insurance expenses for children in the first five years of life - a cohort-based analysis].
    Reichert J; Schemken M; Manthei R; Steinbronn R; Bucher U; Albrecht M; Rüdiger M
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):451-60. PubMed ID: 24238022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
    Haas JS; Phillips KA; Gerstenberger EP; Seger AC
    Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.